Heart Failure Therapy Optimisation in a Patient With Significant Mitral Regurgitation With Transeptal Mitral Valve Replacement, HighLife Valve, and 3-Years Follow-Up

Heart failure therapy optimisation with significantly improved outcomes has been shown with transcatheter edge-to-edge repair (TEER) in patients with persistent and significant residual mitral regurgitation (MR) despite full medical and device therapy. The feasibility of transcatheter transeptal mitral valve replacement (TSMVR) for these patients is unknown.
Source: Heart, Lung and Circulation - Category: Cardiology Authors: Source Type: research